2008
DOI: 10.1017/s0029665108006307
|View full text |Cite
|
Sign up to set email alerts
|

PUFA in the pathogenesis and treatment of patients with multiple sclerosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0
1

Year Published

2009
2009
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 2 publications
0
2
0
1
Order By: Relevance
“…The authors reported that a dose of 5 g/day over 18 months produced no benefit whatsoever on any parameter of disease activity, surrogate or otherwise. A dose of 14 g/day on the other hand, over the same time period, significantly reduced the annualised mean of relapses per patient and the levels of disability as measured by EDSS scores [265].…”
Section: Lipid Rafts Mlrs and N-3 Pufas In Multiple Sclerosismentioning
confidence: 78%
“…The authors reported that a dose of 5 g/day over 18 months produced no benefit whatsoever on any parameter of disease activity, surrogate or otherwise. A dose of 14 g/day on the other hand, over the same time period, significantly reduced the annualised mean of relapses per patient and the levels of disability as measured by EDSS scores [265].…”
Section: Lipid Rafts Mlrs and N-3 Pufas In Multiple Sclerosismentioning
confidence: 78%
“…A linhaça é fonte dos ácidos graxos α-linolênico e linoléico, precursores do ω-3 e ω-6, respectivamente. Tais ácidos são importantes para o desenvolvimento do sistema nervoso central, auxiliam na prevenção de doenças cardiovasculares, diabetes e determinados tipos de câncer, atuam ainda na redução de processos inflamatórios e doenças auto--imunes 7 .…”
Section: N T R O D U ç ã Ounclassified
“…E-mail: pa.cremonez@gmail.com. (FAO, 2008;Oomah and Mazza, 1993;Westcott and Muir, 2003;Harbige et al, 2008).…”
Section: Introductionmentioning
confidence: 99%